^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MAGI2-AS3 (MAGI2 Antisense RNA 3)

    i
    Other names: MAGI2-AS3, MAGI2 Antisense RNA 3, MAGI2 Antisense RNA 3 (Non-Protein Coding), ENST00000414797, NONHSAG048073.2, HSALNG0059170, MAGI2-AS3
    Associations

    News

    Trials
    4ms
    miR-142-3p as a Candidate Biomarker for Early-Stage Lung Adenocarcinoma: Integrative Bioinformatics Analysis and experimental Validation. (PubMed, Biomarkers)
    miR-142-3p also showed diagnostic potential through receiver operating characteristic (ROC) analysis (AUC = 0.8481). All the results implied that miR-142-3p can be a candidate biomarker for the early detection and diagnosis of LUAD.
    Journal
    |
    MIR142 (MicroRNA 142) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
    4ms
    Genomic data mining reveals hub genes and lncRNAs as prognostic biomarkers in breast cancer. (PubMed, Sci Rep)
    This study provides a blueprint for identifying mRNA-lncRNA networks in any cancer, facilitating the use of lncRNAs as prognostic biomarkers and aiding in the identification of therapeutic targets. Future research may focus on validating this research biologically to further substantiate the role of lncRNAs as prognostic biomarkers in breast cancer.
    Journal
    |
    MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • LINC00667 (Long Intergenic Non-Protein Coding RNA 667) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
    5ms
    Hypermethylated Long Non-Coding RNA Genes KCNK15-AS1, MAGI2-AS3, and SSTR5-AS1 in Ovarian Cancer and Their Diagnostic Potential. (PubMed, Bull Exp Biol Med)
    The developed marker panel may be of interest for the molecular assessment of at-risk patients when determining a preliminary diagnosis. However, the method requires validation on a larger, more representative sample set.
    Journal
    |
    SSTR5 (Somatostatin Receptor 5) • SSTR5-AS1 (SSTR5 Antisense RNA 1) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
    5ms
    The neuroprotective effect of LncRNA MAGI2-AS3 against cerebral ischemia-reperfusion injury via targeting miR-218-5p. (PubMed, J Stroke Cerebrovasc Dis)
    MAGI2-AS3 was initially identified as a potential protective agent against circulatory CIR. It exerts neuroprotective effects by targeting miR-218-5p, thereby alleviating neurological damage caused by such injury.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR218 (MicroRNA 218) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
    6ms
    Exploring EZH2-Linked lncRNAs in Gastric Cancer: Insights from Sequencing Data and Gene Modulation. (PubMed, Biochem Genet)
    EZH2 modulates the expression of several key lncRNAs associated with gastric cancer progression, suggesting that the EZH2/lncRNA axis could serve as a potential therapeutic target. Targeting this axis may open new avenues for influencing critical molecular pathways involved in GC development.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • PVT1 (Pvt1 Oncogene) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
    7ms
    The lncRNA MAGI2-AS3 in peripheral blood mononuclear cells: a valuable biomarker for diagnosis and prognosis prediction of breast cancer. (PubMed, PeerJ)
    MAGI2-AS3 expression in breast cancer patients' PBMCs is reduced and negatively correlated with patient outcomes. Thus, it has the potential to be a valuable biomarker for breast cancer diagnosis and prognostic evaluation.
    Journal
    |
    MAGI2-AS3 (MAGI2 Antisense RNA 3)
    8ms
    MAGI2-AS3/miR-450b-5p/COLEC10 interaction network: A potential therapeutic and prognostic marker in hepatocellular carcinoma. (PubMed, ILIVER)
    Correlation analysis revealed that a MAGI2-AS3/hsa-miR-450b-5p/COLEC10 axis might play a crucial role in the progression of HCC. The ceRNA network constructed could provide insight into HCC tumorigenesis and might lead to new molecular biomarkers for diagnosing and treating HCC.
    Journal
    |
    RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • MCM10 (Minichromosome Maintenance 10 Replication Initiation Factor) • ALYREF (Aly/REF Export Factor) • CDK3 (Cyclin Dependent Kinase 3) • COLEC10 (Collectin Subfamily Member 10) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
    8ms
    Expression of Concern. (PubMed, Eur Rev Med Pharmacol Sci)
    Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway...PMID: 33577026. The Publisher apologizes for any inconvenience this may cause.
    Journal
    |
    IGF2 (Insulin-like growth factor 2) • MIR200B (MicroRNA 200b) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • FUS (FUS RNA Binding Protein) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • AFAP1-AS1 (AFAP1 Antisense RNA 1) • FOXO3 (Forkhead box O3) • PCNA (Proliferating cell nuclear antigen) • GAS5 (Growth Arrest Specific 5) • SMAD7 (SMAD Family Member 7) • DSCAM (DS Cell Adhesion Molecule) • HOXA-AS2 (HOXA Cluster Antisense RNA 2) • MIR29A (MicroRNA 29a) • MIR483 (MicroRNA 483) • MMP7 (Matrix metallopeptidase 7) • RBM24 (RNA Binding Motif Protein 24) • SNHG7 (Small Nucleolar RNA Host Gene 7) • TGFBR1 (Transforming Growth Factor Beta Receptor 1) • TGIF2 (TGFB Induced Factor Homeobox 2) • WTAP (WT1 Associated Protein) • XIST (X Inactive Specific Transcript) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
    |
    cisplatin
    1year
    Analysis and exploration of regulatory mechanisms and potential prognostic biomarkers in squamous cell carcinoma of the lung by expression profiling. (PubMed, Transl Cancer Res)
    A significant association was also found between MAGI2-AS3 and the expression of MBNL2 (R=0.51). High expression of MBNL2 inhibits cancer cell proliferation and migration, yet promotes cancer cell apoptosis.
    Journal
    |
    CASP3 (Caspase 3) • CASP7 (Caspase 7) • XBP1 (X-box-binding protein 1) • PDLIM3 (PDZ And LIM Domain 3) • ZFP36 (ZFP36 Ring Finger Protein) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
    1year
    MAGI2-AS3 hypermethylated in promoter region promotes migration and invasion of head and neck squamous cell carcinoma via miRNA-31-5p/AR axis. (PubMed, Transl Oncol)
    Thus, MAGI2-AS3 could inhibit the proliferation, migration, and invasion of HNSCC through the miR-31-5p/AR axis. This provided a theoretical basis that MAGI2-AS3 was a potential therapeutic target for HNSCC.
    Journal
    |
    MIR31 (MicroRNA 31) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
    |
    AR expression
    over1year
    LncRNA MAGI2-AS3 enhances cisplatin sensitivity of non-small cell lung cancer cells by regulating the miR-1269a/PTEN/AKT pathway (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
    MAGI2-AS3 enhances DDP sensitivity of NSCLC by targeted regulation of the miR-1269a/PTEN/AKT signaling axis.
    Journal
    |
    MIR1269A (MicroRNA 1269a) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
    |
    PTEN expression
    |
    cisplatin
    over1year
    Tumor Heterogeneity in Gastrointestinal Cancer Based on Multimodal Data Analysis. (PubMed, Genes (Basel))
    By harnessing multimodal features, our study enhances the understanding of gastrointestinal tumor heterogeneity and identifies biomarkers for personalized medicine and targeted treatments.
    Journal
    |
    MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • MAGI2-AS3 (MAGI2 Antisense RNA 3)